Metropolis

Stock market today: The Centre has elevated IRCTC and IRFC from Miniratna I to Navratna status

This is the second acquisition in the North India market this financial year; share of North market to grow from 8 per cent now to 18 per cent by end of FY26

Market share gains in the B2C portfolio are visible and Tier III+ markets are likely to contribute to the patient volume growth guidance

Diagnostic chain Metropolis Healthcare on Monday said it will acquire Core Diagnostics for Rs 247 crore. The company's board has approved the acquisition of 100 per cent stake in Core Diagnostics from its existing shareholder Core Diagnostics (Mauritius) Pvt Ltd, Metropolis Healthcare said in a regulatory filing. Pursuant to the completion of acquisition, Core Diagnostics will become a wholly owned subsidiary of the company, it added. "This strategic acquisition will enhance Metropolis Healthcare's advanced cancer testing capabilities and strengthen its footprint in northern and eastern India," the diagnostic chain said. By leveraging Core Diagnostics' strong relationships with leading cancer specialists and hospitals in these regions, Metropolis aims to expand its market reach and specialised testing offerings, it added. "With approximately 1.4 million new cancer cases and nearly a million deaths annually in India, there is a critical need for advanced cancer testing nationwide.

On a sequential basis, the company exhibited a 5.63 per cent decline in revenue along with PAT, which declined by 23.41 per cent

The diagnostic player has also taken price hikes in the range of 4-5 percent in the last three years

In a Q&A, the promoter and MD of the company talks about how the dynamics are changing in the diagnostics sector post Covid, and outlines her strategy for Metropolis 3.0

Vinay Rajani of HDFC Securities is bullish on Metropolis, Zensar Tech.

The development of Haryana's golden goose has thrived despite reflecting all the worst contradictions of post-liberalisation India

Metropolis, Dr Lal and Thyrocare are likely to see more gains led by expansion, increasing penetration, preventive testing and government's Ayushman Bharat scheme

Price caps on tests and competitive nature of the sector could test the high valuations

Metropolis has 1,200 collection centres and a presence in six countries

The Rs 650 cr firm, in which PE nvestor Carlyle holds 30%, will opt for an IPO or Private equity to finance acquisition